Plasmin(ogen) at the Nexus of Fibrinolysis, Inflammation, and Complement

Abstract

The diverse mechanisms by which the plasmin(ogen) system is involved in human physiology and pathology are constantly being delineated. For many years, the plasmin(ogen) system was chiefly known as the system responsible for vascular fibrinolysis. Although this is an important function of the plasmin(ogen) system, we now recognize that plasmin(ogen) is critically important as a mediator of inflammation and the innate immune system, which impacts upon a diverse set of mechanisms underlying the pathologies of many diseases. The current review focuses on recent developments in plasmin(ogen) system activation and regulation and how dysregulation of this finely tuned system may contribute to inflammatory disease (atherosclerosis), impaired wound healing, and infection.

Keywords

fibrinolysis - plasminogen receptors - inflammation - complement - wound healing

• References

• 1 Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984; 74 (6) 1988-1995
• 2 Shatos MA, Orfeo T, Doherty JM, Penar PL, Collen D, Mann KG. Alpha-thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells. Arterioscler Thromb Vasc Biol 1995; 15 (7) 903-911
• 3 Kim PY, Tieu LD, Stafford AR, Fredenburgh JC, Weitz JI. A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem 2012; 287 (7) 4652-4661
• 4 Horrevoets AJ, Pannekoek H, Nesheim ME. A steady-state template model that describes the kinetics of fibrin-stimulated [Glu1]- and [Lys78]plasminogen activation by native tissue-type plasminogen activator and variants that lack either the finger or kringle-2 domain. J Biol Chem 1997; 272 (4) 2183-2191
• 5 Walker JB, Nesheim ME. A kinetic analysis of the tissue plasminogen activator and DSPAalpha1 cofactor activities of untreated and TAFIa-treated soluble fibrin degradation products of varying size. J Biol Chem 2001; 276 (5) 3138-3148
• 6 Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 1986; 261 (3) 1253-1258
• 7 Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. Thromb Res 1983; 29 (4) 407-417
• 8 de Maat S, Björkqvist J, Suffritti C , et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 2016; 138 (5) 1414-1423.e9
• 9 Foley JH, Cook PF, Nesheim ME. Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites. J Biol Chem 2011; 286 (22) 19280-19286
• 10 Godier A, Hunt BJ. Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease. J Thromb Haemost 2013; 11 (1) 26-34
• 11 Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 9 (10) 939-945
• 12 Ditzel HJ, Strik MC, Larsen MK , et al. Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. J Biol Chem 2002; 277 (24) 21712-21722
• 13 Seipelt J, Liebig HD, Sommergruber W, Gerner C, Kuechler E. 2A proteinase of human rhinovirus cleaves cytokeratin 8 in infected HeLa cells. J Biol Chem 2000; 275 (26) 20084-20089
• 14 Vaisar T, Kassim SY, Gomez IG , et al. MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages. Mol Cell Proteomics 2009; 8 (5) 1044-1060
• 15 Jevnikar Z, Obermajer N, Doljak B , et al. Cathepsin X cleavage of the beta2 integrin regulates talin-binding and LFA-1 affinity in T cells. J Leukoc Biol 2011; 90 (1) 99-109
• 16 Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem 2004; 279 (42) 43411-43418
• 17 MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem 2003; 278 (28) 25577-25584
• 18 Kassam G, Le BH, Choi KS , et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. Biochemistry 1998; 37 (48) 16958-16966
• 19 Swisher JF, Khatri U, Feldman GM. Annexin A2 is a soluble mediator of macrophage activation. J Leukoc Biol 2007; 82 (5) 1174-1184
• 20 Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001; 58 (7) 902-920
• 21 Das R, Burke T, Plow EF. Histone H2B as a functionally important plasminogen receptor on macrophages. Blood 2007; 110 (10) 3763-3772
• 22 Das R, Burke T, Van Wagoner DR, Plow EF. L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages. Circ Res 2009; 105 (2) 167-175
• 23 Das R, Plow EF. Phosphatidylserine as an anchor for plasminogen and its plasminogen receptor, histone H2B, to the macrophage surface. J Thromb Haemost 2011; 9 (2) 339-349
• 24 Andronicos NM, Chen EI, Baik N , et al. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood 2010; 115 (7) 1319-1330
• 25 Abdul S, Leebeek FW, Rijken DC, Uitte de Willige S. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences. Blood 2016; 127 (5) 538-545
• 26 Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem 1991; 266 (19) 12329-12336
• 27 Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279 (14) 13333-13339
• 28 Wu C, Kim PY, Swystun LL, Liaw PC, Weitz JI. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells. J Thromb Haemost 2016; 14 (2) 366-374
• 29 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96 (5) 2534-2538
• 30 Wygrecka M, Marsh LM, Morty RE , et al. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 2009; 113 (22) 5588-5598
• 31 Schlechte W, Murano G, Boyd D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 1989; 49 (21) 6064-6069
• 32 Jimenez JJ, Iribarren JL, Lorente L , et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care 2007; 11 (6) R117
• 33 Jiménez JJ, Iribarren JL, Brouard M , et al. Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial. J Cardiothorac Surg 2011; 6: 138
• 34 Later AF, Sitniakowsky LS, van Hilten JA , et al. Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery. J Thorac Cardiovasc Surg 2013; 145 (6) 1611-1616 , 1616.e1–1616.e4
• 35 Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003; 126 (5) 1498-1503
• 36 Graham EM, Atz AM, Gillis J , et al. Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J Thorac Cardiovasc Surg 2012; 143 (5) 1069-1076
• 37 Renckens R, Weijer S, de Vos AF , et al. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004; 24 (3) 483-488
• 38 Del Rosso M, Fibbi G, Pucci M, Margheri F, Serrati S. The plasminogen activation system in inflammation. Front Biosci 2008; 13: 4667-4686
• 39 Romer J, Bugge TH, Pyke C , et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996; 2 (3) 287-292
• 40 Yuasa M, Mignemi NA, Nyman JS , et al. Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification. J Clin Invest 2015; 125 (8) 3117-3131
• 41 Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 2005; 166 (3) 783-792
• 42 Kremen M, Krishnan R, Emery I , et al. Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc Natl Acad Sci U S A 2008; 105 (44) 17109-17114
• 43 Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009; 148: 43-66
• 44 Syrovets T, Jendrach M, Rohwedder A, Schüle A, Simmet T. Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood 2001; 97 (12) 3941-3950
• 45 Burysek L, Syrovets T, Simmet T. The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 2002; 277 (36) 33509-33517
• 46 Weide I, Tippler B, Syrovets T, Simmet T. Plasmin is a specific stimulus of the 5-lipoxygenase pathway of human peripheral monocytes. Thromb Haemost 1996; 76 (4) 561-568
• 47 Syrovets T, Tippler B, Rieks M, Simmet T. Plasmin is a potent and specific chemoattractant for human peripheral monocytes acting via a cyclic guanosine monophosphate-dependent pathway. Blood 1997; 89 (12) 4574-4583
• 48 Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J Biol Chem 2002; 277 (37) 33564-33570
• 49 Laumonnier Y, Syrovets T, Burysek L, Simmet T. Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes. Blood 2006; 107 (8) 3342-3349
• 50 Li X, Syrovets T, Genze F , et al. Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response. Arterioscler Thromb Vasc Biol 2010; 30 (3) 582-590
• 51 Borg RJ, Samson AL, Au AE , et al. Dendritic cell-mediated phagocytosis but not immune activation is enhanced by plasmin. PLoS ONE 2015; 10 (7) e0131216
• 52 Shen Y, Guo Y, Du C, Wilczynska M, Hellström S, Ny T. Mice deficient in urokinase-type plasminogen activator have delayed healing of tympanic membrane perforations. PLoS ONE 2012; 7 (12) e51303
• 53 Lund LR, Green KA, Stoop AA , et al. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J 2006; 25 (12) 2686-2697
• 54 Shen Y, Guo Y, Mikus P , et al. Plasminogen is a key proinflammatory regulator that accelerates the healing of acute and diabetic wounds. Blood 2012; 119 (24) 5879-5887
• 55 Carmeliet P, Moons L, Lijnen R , et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17 (4) 439-444
• 56 Ajjan RA, Gamlen T, Standeven KF , et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood 2013; 122 (1) 134-142
• 57 Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340 (2) 115-126
• 58 Viola J, Soehnlein O. Atherosclerosis – a matter of unresolved inflammation. Semin Immunol 2015; 27 (3) 184-193
• 59 Tkachuk V, Stepanova V, Little PJ, Bobik A. Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin Exp Pharmacol Physiol 1996; 23 (9) 759-765
• 60 Hu JH, Du L, Chu T , et al. Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice. Circulation 2010; 121 (14) 1637-1644
• 61 Hu JH, Touch P, Zhang J , et al. Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor. Cardiovasc Res 2015; 105 (3) 372-382
• 62 Foley JH, Walton BL, Aleman MM , et al. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine 2016; 5: 175-182
• 63 Amara U, Flierl MA, Rittirsch D , et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185 (9) 5628-5636
• 64 Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem 2012; 287 (22) 18831-18842
• 65 Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J 2015; 34 (22) 2735-2757
• 66 Huber-Lang M, Sarma JV, Zetoune FS , et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12 (6) 682-687
• 67 Castiblanco-Valencia MM, Fraga TR, Pagotto AH , et al. Plasmin cleaves fibrinogen and the human complement proteins C3b and C5 in the presence of Leptospira interrogans proteins: A new role of LigA and LigB in invasion and complement immune evasion. Immunobiology 2016; 221 (5) 679-689
• 68 Agrahari G, Liang Z, Glinton K, Lee SW, Ploplis VA, Castellino FJ. Streptococcus pyogenes Employs Strain-dependent Mechanisms of C3b Inactivation to Inhibit Phagocytosis and Killing of Bacteria. J Biol Chem 2016; 291 (17) 9181-9189
• 69 Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science 1992; 258 (5084): 1004-1007
• 70 Koch TK, Reuter M, Barthel D , et al. Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. PLoS ONE 2012; 7 (10) e47638
• 71 Barthel D, Singh B, Riesbeck K, Zipfel PF. Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity. J Immunol 2012; 188 (1) 379-385
• 72 Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5 (Suppl. 01) 24-31
• 73 Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol 2008; 6 (2) 132-142
• 74 Shao Z, Nishimura T, Leung LL, Morser J. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. J Thromb Haemost 2015; 13 (6) 1090-1102
• 75 Song JJ, Hwang I, Cho KH , et al; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011; 121 (9) 3517-3527
• 76 Myles T, Nishimura T, Yun TH , et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278 (51) 51059-51067
• 77 Nishimura T, Myles T, Piliponsky AM, Kao PN, Berry GJ, Leung LL. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007; 109 (5) 1992-1997
• 78 Ward PA. A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med 1967; 126 (2) 189-206
• 79 Foley JH, Peterson EA, Lei V, Wan LW, Krisinger MJ, Conway EM. Interplay between fibrinolysis and complement: plasmin cleavage of iC3b modulates immune responses. J Thromb Haemost 2015; 13 (4) 610-618
• 80 Wojta J, Kaun C, Zorn G , et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002; 100 (2) 517-523
• 81 Kastl SP, Speidl WS, Kaun C , et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J Thromb Haemost 2006; 4 (8) 1790-1797
• 82 Howes JM, Richardson VR, Smith KA , et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9 (3) 216-225
• 83 Hess K, Alzahrani SH, Mathai M , et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2012; 55 (4) 1103-1113
• 84 Hess K, Alzahrani SH, Price JF , et al. Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. Diabetologia 2014; 57 (8) 1737-1741
• 85 Nikolajsen CL, Scavenius C, Enghild JJ. Human complement C3 is a substrate for transglutaminases. A functional link between non-protease-based members of the coagulation and complement cascades. Biochemistry 2012; 51 (23) 4735-4742
• 86 Richardson VR, Schroeder V, Grant PJ, Standeven KF, Carter AM. Complement C3 is a substrate for activated factor XIII that is cross-linked to fibrin during clot formation. Br J Haematol 2013; 160 (1) 116-119